McKesson (MCK)
(Delayed Data from NYSE)
$613.00 USD
+5.49 (0.90%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $613.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$613.00 USD
+5.49 (0.90%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $613.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View
by Zacks Equity Research
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Quest Diagnostics (DGX) Q3 Earnings Surpass, View Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to accelerate volume growth in Q3.
Cerner's (CERN) AbleVets Buyout to Boost Federal Services
by Zacks Equity Research
Cerner (CERN) expects to close the AbleVets deal in the fourth quarter of 2019.
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
McKesson (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Intuitive Surgical (ISRG) Beats on Q3 Earnings, View Solid
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid segmental contributions in Q3.
Top Ranked Value Stocks to Buy for October 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 18th.
Here's Why You Should Add PRA Health to Your Portfolio Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.
Here's Why You Should Add Allscripts to Your Portfolio Now
by Zacks Equity Research
Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.
Here's Why You Should Retain Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.
Here's Why You Should Hold on to NextGen Healthcare for Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) raises 2019 revenue and earnings per share guidance.
Top Ranked Value Stocks to Buy for October 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 15th.
Here's Why You Should Retain Ecolab (ECL) Stock For Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.
Integer Holdings (ITGR) Boosts Product Line with New Buyout
by Zacks Equity Research
Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.
Top Ranked Value Stocks to Buy for October 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 8th
Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.